About UR Advanced Therapeutics
UR Advanced Therapeutics is a Healthcare company based in Hyderabad (India). It designs peptides for tissue engineering, drug discovery, and lab services. It operates on a B2B model. The company has 1 employees. Its Indian entity Ur Advanced Therapeutics Private Limited reported revenue of ₹56.9 Lakh. UR Advanced Therapeutics offers products and services including Dynamic Apoptosis Detection (DAD)-Kit, CytoFLASH, ViaBLUE Cell Proliferation Kit, High-Expression Bacterial Vectors, and Wet Laboratory Services. Its focus areas include Biotechnology, Drug Discovery, In-silico Biology and Therapeutics.
Company details
UR Advanced Therapeutics engineers personalized medicine using biomaterials and stem cell technologies. They design de novo peptides for applications in tissue engineering, therapeutics, and drug discovery. Based in Hyderabad, India, they offer products like detection kits and services including cell cultures, flow cytometry, and in-silico analysis. Their focus is on advancing scientific research without promoting specific outcomes.
- Headquarters Hyderabad, India
- Employees 1
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website uratpx.com
- Social Facebook
- Legal Name Ur Advanced Therapeutics Private Limited
- Date of Incorporation 17 Jul, 2020
- Jurisdiction Hyderabad, Telangana, India
- Annual Revenue₹56.9 Lakh
FY 2025 · +80% YoY
- Net Loss-₹34 Lakh
FY 2025 · -60% margin
- EBITDA₹15.6 Lakh
FY 2025 · 27% margin
- Employee Count1
Associated legal entities of UR Advanced Therapeutics
UR Advanced Therapeutics operates through Ur Advanced Therapeutics Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Ur Advanced Therapeutics Private Limited CIN U73100TG2020PTC141847 | Active | 17 Jul 2020 | Hyderabad, Telangana | ₹0.6 Cr | 4 | View details |
Products & Services of UR Advanced Therapeutics
UR Advanced Therapeutics offers a comprehensive portfolio of products and services, including Dynamic Apoptosis Detection (DAD)-Kit, CytoFLASH, ViaBLUE Cell Proliferation Kit, High-Expression Bacterial Vectors, and Wet Laboratory Services.
Kit for early and late apoptosis detection in cells.
Fluorescent biosensor for identifying live proliferating cells.
Assay to quantitate live cells with high signal sensitivity.
Custom promoters for over-expression of genes of interest.
Provides cell cultures and drug screening for research.
Offers data analysis and molecular docking for drug discovery.
Board of directors of Ur Advanced Therapeutics Private Limited (UR Advanced Therapeutics)
Ur Advanced Therapeutics Private Limited is the primary company behind UR Advanced Therapeutics. The board of Ur Advanced Therapeutics Private Limited currently have 4 directors; the longest-serving is Jangamreddy Jagan Mohan Reddy, appointed in 2020. 4 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Jangamreddy Jagan Mohan Reddy DIN 08797859 | Director | 17 Jul 2020 | 6 yrs 3 mo | Ur Advanced Therapeutics Private Limited |
| Aparna Rachamallu DIN 09521061 | Director | 16 Mar 2023 | 3 yrs 7 mo | Ur Advanced Therapeutics Private Limited |
| Sai Pooja Anne DIN 10402017 | Director | 16 Dec 2023 | 2 yrs 10 mo | Ur Advanced Therapeutics Private Limited |
| Bhanu Prasad Kommineni DIN 01408377 | Director | 16 Dec 2023 | 2 yrs 10 mo | Ur Advanced Therapeutics Private Limited |
Financials of UR Advanced Therapeutics
Figures of Ur Advanced Therapeutics Private Limited, the primary company behind UR Advanced Therapeutics, for FY 2025. Revenue was ₹56.9 Lakh (+80% year on year). Net loss was -₹34 Lakh (-60% margin). EBITDA was ₹15.6 Lakh (27% margin). Revenue has grown at a compounded annual rate of +167% over three years.
- ₹56.9 LakhRevenue · FY 2025 · +80% YoY
- -₹34 LakhNet loss · -60% margin
- ₹15.6 LakhEBITDA · 27% margin
- ₹1.30 CrPaid-up capital
- +167%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Ur Advanced Therapeutics Private Limited are on its company page.
Detailed financial statements for UR Advanced Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about UR Advanced Therapeutics
UR Advanced Therapeutics is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
UR Advanced Therapeutics has 1 employees.
The primary company behind UR Advanced Therapeutics, Ur Advanced Therapeutics Private Limited, reported revenue of ₹56.9 Lakh for FY 2025, up 80% year on year.
UR Advanced Therapeutics engineers personalized medicine using biomaterials and stem cell technologies. They design de novo peptides for applications in tissue engineering, therapeutics, and drug discovery. Based in Hyderabad, India, they offer products like detection kits and services including cell cultures, flow cytometry, and in-silico analysis. Their focus is on advancing scientific research without promoting specific outcomes.
UR Advanced Therapeutics offers Dynamic Apoptosis Detection (DAD)-Kit, CytoFLASH, ViaBLUE Cell Proliferation Kit, High-Expression Bacterial Vectors, and 2 more products and services.
UR Advanced Therapeutics operates through Ur Advanced Therapeutics Private Limited.
The legal entities of UR Advanced Therapeutics currently have 4 directors, including Sai Pooja Anne, Aparna Rachamallu, Jangamreddy Jagan Mohan Reddy and others.